Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

• Asıl Yazarlar: Eugenia Veronica Di Brizzi (Yazar), Stefano Caccavale (Yazar), Roberta Di Caprio (Yazar), Francesco Cusano (Yazar), Rocco De Pasquale (Yazar), Valeria Falcomatà (Yazar), Caterina Foti (Yazar), Claudia Giofrè (Yazar), Emanuela Gubinelli (Yazar), Giampiero Mazzocchetti (Yazar), Massimiliano Nicolini (Yazar), Giovanni Palazzo (Yazar), Leonardo Pescitelli (Yazar), Rosa Valentina Puca (Yazar), Oriele Sarno (Yazar), Anna Balato (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Mattioli1885, 2024-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life. Objectives: The study aimed to ident...